Methylphenidate. An update on extended-release formulations

Abstract

Methylphenidate remains the mainstay of pharmacological management in attention deficit hyperactivity disorder (ADHD). Despite having been available for over half a century, methylphenidates original formulation has been modified with the main purpose of extending its duration of action. This article will present a brief review of how these new formulations vary and how these should be selected, considering the evidence available on their effectiveness and on the individual needs of the patient.